MARCKS and breast carcinoma: BM-MSCs-derived EVs promote a dormant phenotype in metastatic breast cancer cells via the miR-23b/myristoylated alanine-rich C-kinase substrate (MARCKS) axis [258] and Wnt-β-catenin signaling-mediated dedifferentiation [259].